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Abstract
Background: Prostate cancer (PC) is a major health concern for men worldwide, with an estimated lifetime risk of
~14 %. A recent comprehensive analysis of mutational processes revealed ageing and mismatch repair as the only
altered processes in PC. We wish to test if a cohort of men with inherited risk of mismatch repair defect through
BRCA1/2 or Lynch Syndrome mutations represents a target population for prostate cancer testing.
Methods: Fifty-eight men (aged 40–69 years) from families with a history of BRCA1/2 or HNPCC/Lynch mutations
were invited to take part. Men with PSA >3.0 ng/ml were recommended to have transrectal ultrasound-guided
prostatic biopsies.
Results: Overall 1 of 7 (14 %) and 1 of 20 (5 %) men with BRCA1/2 mutations were positive for a diagnosis of
prostate cancer. In men with Lynch syndrome, 1 of 4 (25 %) was diagnosed to have prostate cancer. The index case
with Lynch syndrome harbours a heterozygous mutation in the mismatch repair MSH6 gene. Near to complete loss
of MSH6 immunoreactivity in the prostate tumour supports silencing of the remaining MSH6 allele during prostate
carcinogenesis.
Conclusion: The finding of near-to-complete loss of MSH6 expression in affected men with a family history of
Lynch Syndrome supports its mechanistic involvement during prostate carcinogenesis. This work therefore
contributes to the argument that, in certain male populations, Lynch Syndrome mutations are biologically
implicated in men with prostate cancer.
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Background
Prostate cancer (PC) is the commonest solid malignancy
diagnosed in men in the Western world, and the second
leading cause of male cancer death. The estimated
lifetime risk of prostate cancer is reported to be at
~14–18 %, with a median age of 66 years at diagnosis
[1]. Genetic factors contribute to at least 40 % of all
PC in patients under 50 [2].
BRCA1 and BRCA2 (breast cancer 1/2, early onset) as
key molecules for the homologous recombination path-
way to repair double-strand DNA breaks are intrinsically
involved in the maintenance of the genome stability.
Inherited mutations in the BRCA1 and BRCA2 genes
confer increased lifetime risk of developing breast and/
or ovarian cancer. Hereditary Non-polyposis Colorectal
Cancer (HNPCC) or Lynch syndrome, an autosomal
dominant hereditary cancer trait, carries a genetic pre-
disposition to colorectal cancer with an 80 % lifetime
risk of colorectal cancer, accounting for 1–5 % of all
colorectal cancers as well as other cancers including
endometrial, gastric, ovarian, urinary tract, pancreatic,
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brain and sebaceous tumours [3]. Collectively, men with
germline mutations in BRCA1, BRCA2 or HNPCC
(Lynch syndrome) are reported to be at increased risk of
developing PC [4, 5].
Most reported studies in literature have described
findings in isolation on men with individual risk factors.
Here, we present our cohort of men with a family history
for one of the two inherited syndromes, focusing on
individuals with elevated Prostate Specific Antigen (PSA)
levels that warrant diagnostic prostatic biopsies.
Methods
Patient cohort
From 2010, with appropriate ethics and Health Board
approvals, the West of Scotland Regional Genetic Service,
in collaboration with local Urology Service, invited men
aged 40–69 years of age from families with a history of
BRCA1/2 mutations to take part in this study. From 2013,
men with a family history of Lynch mutations (MLH1,
MSH2, MSH6, [PMS2 not included]) were also included.
The reference for ethics approval for the study (as part of
the IMPACT study) is 05/MRE07/25. Informed consent to
participate in this study was obtained from all participants.
All data presented in the report are presented in an
anonymous manner in keeping with ethics approval.
Men were excluded if they were known to have PC
or if they had a prior cancer diagnosis with a prognosis
of <5 years. Participants underwent PSA testing at en-
rolment, and if their PSA value exceeded 3.0 ng/ml,
10 to 12-core transrectal ultrasound– (TRUS-) guided
prostate biopsies were recommended. Participants with
PSA ≤3.0 ng/ml underwent annual PSA screening for
≥5 year. Participants with PSA >3.0 ng/ml and a negative
biopsy will undergo annual PSA testing, repeating the
biopsy if PSA increases by >50 %.
Immunohistochemistry (IHC)
Tissue sections were processed sequentially: (1) Deparaf-
finisation at 72 °C, with Cell Conditioning using CC1
at 100 °C for 72 min; (2) Incubation with primary
antibody for 1 h; and (3) Counterstain with Haematoxylin
for 8 min and Bluing Reagent for 4 min. Standard protocol
for IHC was followed using the Ventana Benchmark
Ultra Machine. Individual primary antibodies were applied
at the following concentrations: MLH1 (Ventana) -
1.4 μg/ml; MSH2 (Cell Marque) - 4.67 μg/ml; PMS2
(Cell Marque) - 2.19 μg/ml; MSH6 (Cell Marque) -
0.101 μg/ml. Visualisation of immuno-reactivity was per-
formed using the Optiview Dab IHC detection Kit.
Microsatellite instability (MSI) analysis
A multiplex PCR protocol was applied for MSI analysis.
Samples for PCR were set up using the 2× Qiagen
Multiplex PCR Kit to amplify five mononucleotide
markers which were fluorescently labeled: BAT25(c-kit),
BAT26(MSH2), NR21(SLC7A8), NR24(ZNF-2) and
MONO27(MAP4K3) [6]. One microlitre of the template
DNA extracted from formalin fixed tissue using the EZ1
Robot (Qiagen) was added to 25 ul PCR reaction. The
following PCR programme was used to amplify selected
markers: (Heated lid at 110 °C) 95 °C for 10 min, then
34 cycles of 94 °C for 1 min, 58 °C for 1 min and 72 °C
1 min, followed by 72 °C for 10 min. Following amplifica-
tion, 1 ul of the PCR products were added to 0.5 ul of
GeneScan™ 500 ROX™ Size Standard (an internal lane size
standard for the Applied Biosystems fluorescence-based
DNA electrophoresis systems) and 8.5 ul of formamide.
Following denaturation (95 °C for 2 min and snap cooled
on ice), the products were run on the 3130 genetic
analyser (Applied Biosystems) and data processed using
Genemarker software. Data supporting the conclusion of
this article are included within the article.
Results
A total of 58 men (mean age of 55.7 years, range: 42–70
years old) were recruited to the study. Eight men were
initially recruited but dropped out of the study, leaving
51 informative cases for analysis: 47 men linked to a
family history of BRCA1/2 mutation and 4 men with
family history of Lynch Syndrome. The mean age and
serum PSA levels were comparable between men from
BRCA1/2 and Lynch Syndrome mutations (Table 1 and
Additional file 1). In accordance to study protocol, pros-
tatic biopsies were offered to individuals with PSA
>3 ng/ml. Four individuals had elevated PSA levels at
the time of recruitment, with a further 3 men showing a
subsequent rise in PSA to exceed 3 ng/ml (Tables 2 and 3).
Among the men with BRCA1/2 mutation history, 2 of the
47 (~4.5 %) men have histological confirmation of PC with
Gleason score 6 disease. Interestingly, both men were posi-
tive for BRCA mutations: 1 for BRCA1 and 1 for BRCA2.
None of the 19 BRCA1/2 mutation negative cases were
diagnosed to have PC (Tables 4 and 5). Overall, 1 of 7
(14 %) and 1 of 20 (5 %) men with BRCA1 and BRCA2
mutations were positive for a diagnosis of PC. Among
the four men with Lynch Syndrome mutations, 1 of 4






BRCA1 +ve (n = 7) 55.6 (42–64) 1.37 (<0.1–4.1)
BRCA1 –ve (n = 7) 59.3 (43–70) 1.84 (0.6–4.1)
BRCA2 +ve (n = 20) 55.7 (42–71) 1.4 (0.3–4.8)
BRCA2 –ve (n = 12) 58.5 (44–72) 1.89 (0.2–3.9)
Lynch +ve (n = 4)a 54.5 (54–56) 3.9 (0.8–11.1)
aAll individuals with family history of Lynch syndrome were positive for
the mutation
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(25 %) was diagnosed to have PC. The BRCA1 affected
man has inherited a heterozygous two base pair deletion
within the BRCA1 gene (c.2681_2682delAA, Genbank
accession number: NM_007294.3) which is predicted
to result in premature termination of the BRCA1 protein,
p.(Lys894Thrfs*8). The heterozygous BRCA2 point
mutation (c.9294C>G, Genbank accession number:
NM_000059.3) identified in the patient with PC re-
sults in premature termination of the BRCA2 protein
p.(Tyr3098*). These two PC sufferers with a genetic
linkage of BRCA1/2 mutations were both found to
have low volume Gleason score 6 diseases, and managed
by active surveillance for over 5 years without clinical
evidence of disease progression.
The individual with Lynch syndrome, diagnosed with
PC, has a familial heterozygous mutation within the MSH6
gene (c.3939_3957dup19, Genbank accession number:
NM_0001791) predicted to result in a truncated MSH6
protein product due to premature termination of the open
reading frame at position 1324, p.(Ala1320SerfsX5). As ex-
pected, this patient has a family history of colorectal cancer
(CRC) with three members affected by CRC. Digital rectal
examination revealed a small, firm prostate with prominent
left lobe. TRUS biopsy showed Gleason score 6 prostate
adenocarcinoma involving 4 out of 6 biopsies from the
left side of the gland. He underwent radical prostatec-
tomy and recovered uneventfully with good urinary
continence, negative (cancer free) surgical margins and
undetectable serum PSA levels. His disease was patho-
logically upgraded to Gleason score 7 disease. Based on
immunohistochemistry analysis, the key mismatch match
repair (MMR) proteins, namely MLH1, PMS2, and MSH2,
were expressed at normal levels, while there was a general
absence of expression for the MSH6 gene, with very
occasional negligible/weak focal immunoreactivity noted
within the tumour (Fig. 1). These expression data on
MSH6 support a causative relationship between inherited
MSH6 gene mutation and prostate carcinogenesis, although
using probes designed for colorectal cancer, microsatellite
instability was not detected in the prostate tumour tissue.
Besides the above patient with PC, among the four men
with Lynch Syndrome mutation, we observed a history of
urological malignancy in a 40 year-old man (with a 7 base
pair deletion within the MSH6 gene) diagnosed with tes-
ticular tumours prior to recruitment to this study, right
sided tumour followed by a left sided tumour 4 years later.
He underwent right inguinal orchidectomy and adjuvant
chemotherapy with bleomycin, etoposide and cisplatin for
his right testicular tumour (non-seminomatous germ cell
tumour). The left testicular tumour was found to be a
mixed germ cell tumour with seminoma, yolk sac tumour
and teratoma following inguinal orchidectomy.
Discussion
The IMPACT study is a large-scale study looking at the
relative risk of men with a history of hereditary BRCA
mutations in developing prostate cancer at a population
level. This report case cohort contributes to the overall
IMPACT study cases. However, none of the prostate can-
cer identified within the IMPACT study would have
undergone investigations to test if the mutated gene was
in fact functionally altered in relation to the development
of prostate cancer. In our report, we carried out molecular
investigation to confirm the presence of mutations in the
affected individuals as well as characterised the expression
levels of the implicated gene (MSH6). We found that there
Table 2 Distribution of PSA levels in the recruited individuals
PSA range (ng/ml) <1 1–1.9 2–2.9 >3
Initial PSA 24 18 5 4
Final PSA 20 18 6 7
Initial PSA = PSA when patients were recruited; Final PSA = PSA level during
the duration of this study
Table 3 Outcome of 7 individuals with elevated PSA levels
undergoing prostatic biopsies
Histology Benign High grade PIN Prostate cancera
Number 3 1 3
aOf three patients positive for prostate cancer, all have Gleason score 6
tumour in diagnostic biopsies
Table 4 Summary of clinic-pathologic parameters of men


















PSA (ng/ml) 4.8 4.1 11.1
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score
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was evidence of loss of expression for this mismatch repair
gene for Lynch Syndrome at the protein level, which pro-
vides indirect mechanistic evidence to support the presence
of molecular event that results in the lost of gene expres-
sion at protein level, in addition to the presence of an inher-
ited mutation in the mismatch repair enzyme gene. A
single mutation in a heterozygous manner would not typic-
ally affect the gene expression as drastic as what we have
observed. In addition, within the recent published IMPACT
series [7], patients with a history of Lynch Syndrome were
not included for analysis. Hence, it remains highly debated
whether men affected by Lynch Syndrome are at risk of de-
veloping prostate cancer. Our report, albeit small, contrib-
utes to the literature in this field. Important publications
arguing for an increased risk for prostate cancer with Lynch
Syndrome are appropriately cited in our report.
Besides changes in genetic profile associated with ageing,
a recent comprehensive analysis of mutational processes in
human cancer has revealed mismatch repair mutations to
be the only genetic signature implicated in PC [8]. Among
the mismatch match repair (MMR) genes, defects within
the MSH2 and MSH6 genes have been previously reported
in patients with PC [9]. In a prospective unbiased analysis
of a cohort of 446 unaffected carriers of an MMR gene mu-
tation (MLH1, MSH2, MSH6, and PMS2) and 1029 of
their unaffected relatives, as part of a Colon Cancer Family
Registry, MMR gene mutation was found to confer in-
creased cancer risks in a number of tumour types recog-
nised to be associated with Lynch Syndrome (colorectal,
endometrial, ovarian, renal, gastric, and urinary bladder),
breast cancer and pancreatic cancer [10]. Importantly, the
non-carrier relatives of family-specific MMR gene muta-
tions did not have increased risks of colorectal or other
cancers, including PC. Bratt et al. identified a two fold in-
creased risk of PC associated with MSH2 mutation [11].
MMR mutation carriers were found to be nearly 6 times
more likely to develop PC [12]: PC occurred at an earlier
age than expected (60.4 years compared with 66.6 years)
and tumours were significantly more aggressive (Gleason
8–10).
BRCA1 and BRCA2 are implicated in homologous-
recombination based DNA double-strand break repair.
BRCA1 is also implicated in mismatch repair, interacting




Fig. 1 Immunohistochemistry of the prostatectomy specimen from patient with Lynch syndrome. MLH1, MSH2 and PMS2 immunoreactivity were
clearly detected in the malignant epithelium. The tumour was mostly negative for MSH6 staining except for a few scattered cells. White arrows
signify MSH6 expression in adjacent smooth muscle cells
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In addition to the genomic structural instability conferred
by defective double-strand break repair, a base substitution
mutational signature in keeping with microsatellite in-
stability, was also associated with BRCA1/2 deficiency [8].
The cumulative lifetime risk of PC among carriers with
mutations in MMR-related genes has been suggested to
be as high as 30 %, compared with ~18 % in the general
population [9]. Our patient cohort is included in the re-
cently published data on the initial screening round of the
IMPACT [15] (Identification of Men with a genetic pre-
disposition to ProstAte Cancer: Targeted screening in
BRCA1/2 mutation carriers and controls; www.impact-
study.co.uk) Study, supporting the notion that men with
BRCA1/2 gene mutations are at increased risk of develop-
ing PC. Overall, from the 2481 recruited men within the
IMPACT study [15], 199 men had PSA >3.0 ng/ml, and
162 men underwent prostatic biopsies. Among biopsied
patients, 59 (or 36 % of) men were found to have PC.
Similarly, in our cohort, 3 of 7 (or 43 %) have positive
biopsies for PC. While 66 % of the PC patients within
the overall IMPACT study have intermediate- or high-
risk disease, all three patients with PC have relatively
low-risk (Gleason 6) disease at diagnosis, although the
single patient undergoing prostatectomy was found to
have his disease upgraded to Gleason 7 tumour. This
data contrast a recent report suggesting that BRCA
mutations were associated with less favouable outcome
following radical treatment [7].
Our study supports the notion that men with a family
history of BRCA1/2 or Lynch Syndrome mutations may
benefit from testing for PC, highlighting the role of MMR
in prostate carcinogenesis. Specifically, our patient with
documented MSH6 mutation and associated loss of its
expression involves a less commonly implicated member
of the MMR genes [16].
Conclusion
The finding of near-to-complete loss of MSH6 expression
in affected men with a family history of Lynch Syndrome
supports its mechanistic involvement during prostate
carcinogenesis. This work therefore contributes to the
argument that, in certain male populations, Lynch Syn-
drome mutations are biologically implicated in men with
prostate cancer.
Additional file
Additional file 1: Tables showing patient details according to the
genetic background. (DOCX 184 kb)
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